1 Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972–80.
2 Anastasilakis AD, Polyzos SA, Makras P, et al. Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. J Bone Miner Res. 2017;32:1291–6.
3 McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM. Observations following discontinuation of long-term denosumab therapy. Osteoporos Int. 2017;28:1723–32.
4 Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of Denosumab: A post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2017 Nov 4.
doi:10.1002/jbmr.3337.
5 Lamy O, Gonzalez-Rodriguez E. Underevaluation of vertebral fractures after denosumab disontinuation. J Bone Miner Res. 2018; in press.
6 Lehmann T. Limitierte Osteoporosebehandlung. Schweiz Med Forum. 2018;18(8):182–4.